Relevant Disclosure with respect to declaration of Dividend by Board of Directors of the Company in their meeting held on May 20, 2025 is attached.
Awaiting price reaction for this filing.
Fortis Healthcare's board, at its May 20, 2025 meeting, approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with a clean (unmodified) audit opinion. The board recommended a final dividend of ₹1 per equity share (10% of the ₹10 face value) for FY25, subject to shareholder approval, to be paid within 30 days of the AGM. Standalone FY25 revenue from operations grew to about ₹1,445.9 crore from ₹1,181.4 crore in FY24, but net profit dropped sharply to ₹63.8 crore from ₹199.5 crore, mainly due to an exceptional loss of ₹115.1 crore (impairment in subsidiary investments). The board also appointed Neelam Gupta & Associates as Secretarial Auditor for five years (2025-2030) and Jitender, Navneet & Co. as Cost Auditor for FY26. The auditor's report flagged ongoing SFIO investigations and Supreme Court/Delhi High Court matters (including the recent ₹200 crore court-led acquisition of the Fortis brand trademark) as emphasis-of-matter items but did not modify the audit opinion.
For shareholders, this is a routine dividend declaration in line with prior years (₹1 per share), modest in absolute terms given the share price. The fall in standalone net profit is driven largely by a one-time impairment, not core operations, which actually showed revenue growth and steady EBITDA — so the dividend payout and audit clean opinion should be reassuring for the stock.